Finland

Desentum secures €12M to advance Birch Pollen Allergy Vaccine Development
Desentum, a biopharmaceutical company based in Espoo, Finland, has announced a significant funding round of €12M to further the clinical development of its birch pollen allergy vaccine, DM-101PX. The investment was led by Springvest Oyj, a Finnish investment firm dedicated to supporting the growth of innovative companies.
Finnish quantum technology company Quanscient has been declared the winner of the global Fujitsu $100,000 Quantum Simulator Challenge. This global competition invited members of the quantum industry and academia to test Fujitsu's 39 qubit quantum simulator on unique problems and applications, aiming to accelerate research on advanced quantum technologies. Quanscient's

The best Articles in our Network

Previous
Next